Drug Detail

Information about SNX-5422

Generic Name
IND	SNX-5422
Brand Name (US)
Manufacturer	Serenex
Drug Type
Delivery	Oral
Approval Status	Discontinued
Indications
Overall Strategy	KIT Protein Based
Strategy	Destroy KIT
Drug Category	HSP90 inhibitor

The development of SNX-5422 has been discontinued because of ocular toxicity seen in animal models and in a phase I study. Clin Cancer Res; 17(21); 1–9. ©2011 AACR.
SNX-5422 is a Heat Shock Protein 90 (Hsp90) inhibitor candidate. SNX-5422 was discovered, designed and synthesized by Serenex scientists.
According to Serenex, in pre-clinical studies, SNX-5422 has high oral bioavailability in all species tested and has demonstrated significant in vivo efficacy across a broad spectrum of tumor types.
SNX-5422 potency and tolerability exceed that of clinical compounds derived from the natural product geldanamycin (17-AAG and 17-DMAG and CNF-1010).